TY - JOUR
T1 - Finasteride increases anagen hair in men with androgenetic alopecia
AU - Van Neste, D.
AU - Fuh, V.
AU - Sanchez-Pedreno, P.
AU - Lopez-Bran, E.
AU - Wolff, H.
AU - Whiting, D.
AU - Roberts, J.
AU - Kopera, D.
AU - Stene, J. J.
AU - Calvieri, S.
AU - Tosti, A.
AU - Prens, E.
AU - Guarrera, M.
AU - Kanojia, P.
AU - He, W.
AU - Kaufman, K. D.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Background. The growth of scalp hair is a cyclical process of successive phases of growth (anagen) and rest (telogen). In previous clinical trials in men with androgenetic alopecia, treatment with finasteride increased scalp hair counts in a defined area (i.e. increased hair density). Objectives. The current study used a phototrichogram methodology to assess the effect of finasteride on the phases of the hair growth cycle. Patients/Methods. Two hundred and twelve men, age 18-40 years, with androgenetic alopecia were randomized to receive finasteride 1 mg daily or placebo for 48 weeks. At baseline and at 24 and 48 weeks, macrophotographs were taken to measure total and anagen hair count in a 1-cm2 target area of the scalp. Results. At baseline, mean total and anagen hair counts in the finasteride group were 200 and 124 hairs, respectively (% anagen = 62%) and the anagen to telogen ratio was 1.74 (geometric mean). In the placebo group, the respective values were 196 and 119 hairs (% anagen = 60%) and 1.57. At week 48, the finasteride group had a net improvement (mean ± SE) compared with placebo in total and anagen hair counts of 17.3 ± 2.5 hairs (8.3% ± 1.4%) and 27.0 ± 2.9 hairs (26% ± 3.1%), respectively (P < 0.001). Furthermore, treatment with finasteride resulted in a net improvement in the anagen to telogen ratio of 47% (P < 0.001). In this study, treatment with finasteride 1 mg day-1 for 48 weeks increased both total and anagen hair counts, and improved the anagen to telogen ratio. Conclusions. These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. These data support that finasteride treatment results in favourable effects on hair quality that contribute to the visible improvements in hair growth observed in treated patients.
AB - Background. The growth of scalp hair is a cyclical process of successive phases of growth (anagen) and rest (telogen). In previous clinical trials in men with androgenetic alopecia, treatment with finasteride increased scalp hair counts in a defined area (i.e. increased hair density). Objectives. The current study used a phototrichogram methodology to assess the effect of finasteride on the phases of the hair growth cycle. Patients/Methods. Two hundred and twelve men, age 18-40 years, with androgenetic alopecia were randomized to receive finasteride 1 mg daily or placebo for 48 weeks. At baseline and at 24 and 48 weeks, macrophotographs were taken to measure total and anagen hair count in a 1-cm2 target area of the scalp. Results. At baseline, mean total and anagen hair counts in the finasteride group were 200 and 124 hairs, respectively (% anagen = 62%) and the anagen to telogen ratio was 1.74 (geometric mean). In the placebo group, the respective values were 196 and 119 hairs (% anagen = 60%) and 1.57. At week 48, the finasteride group had a net improvement (mean ± SE) compared with placebo in total and anagen hair counts of 17.3 ± 2.5 hairs (8.3% ± 1.4%) and 27.0 ± 2.9 hairs (26% ± 3.1%), respectively (P < 0.001). Furthermore, treatment with finasteride resulted in a net improvement in the anagen to telogen ratio of 47% (P < 0.001). In this study, treatment with finasteride 1 mg day-1 for 48 weeks increased both total and anagen hair counts, and improved the anagen to telogen ratio. Conclusions. These data provide direct evidence that finasteride 1 mg daily promotes the conversion of hairs into the anagen phase. These data support that finasteride treatment results in favourable effects on hair quality that contribute to the visible improvements in hair growth observed in treated patients.
KW - Androgenetic alopecia
KW - Finasteride
KW - Increased hair growth
KW - Phototrichogram
KW - Randomized double-blind placebo-controlled clinical trial
KW - Scalp hair counts
UR - http://www.scopus.com/inward/record.url?scp=0033751660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033751660&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2133.2000.03780.x
DO - 10.1046/j.1365-2133.2000.03780.x
M3 - Article
C2 - 11069460
AN - SCOPUS:0033751660
VL - 143
SP - 804
EP - 810
JO - British Journal of Dermatology
JF - British Journal of Dermatology
SN - 0007-0963
IS - 4
ER -